Project Grant R21CA297427
Award Date
12/2/24
Completion Date
11/30/26
Dollars Obligated
$227K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22908, USA
Similar Awards
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $571,496 Project Grant to the University of Toledo Health Science Campus Division to conduct research aimed at understanding the mechanisms by which the tumor-intrinsic TAZ expression regulates the tumor microenvironment and immune suppressive cells like myeloid-derived suppressor cells (MDSCs) in triple-negative breast cancer (TNBC). The research project, titled "Dissecting Molecular Mechanisms of Tumor-Induced...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
This $118,912 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to characterize and overcome major histocompatibility complex class I (MHC-I)-mediated immune evasion in triple-negative breast cancer (TNBC). The primary awardee, the University of North Carolina at Chapel Hill, will conduct experiments to determine how MHC-I loss affects tumor progression and immune cell infiltration, as well as evaluate combination...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $622,329 to Virginia Commonwealth University (VCU) to develop an inhibitor called PDZ1I and evaluate its ability to prevent metastasis and sensitize triple-negative breast cancer (TNBC) to chemotherapies. The award, which runs from August 2024 to July 2029, supports experiments to formulate PDZ1I into a nanocrystal (PDZ1I-nano) for clinical use, characterize how PDZ1I impacts the immune...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to the University of Wisconsin - Madison aims to develop multi-faceted strategies to enhance the treatment efficacy of a platelet-mediated immune checkpoint inhibitor delivery system (P-APDL1) against triple-negative breast cancer (TNBC). The $619,764 award, effective January 10, 2025 through December 31, 2029, will fund research to: 1) increase tumor-selective accumulation of P-APDL1 by...
The federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $647,118 to the University of Colorado-Denver to study the role of the EYA3/PP2A pathway in regulating triple negative breast cancer (TNBC) metastasis. The research aims to determine the molecular and cellular mechanisms by which the EYA3-NF-κB axis enhances TNBC metastasis, and to understand how EYA3 regulates NF-κB signaling through its interaction with the PP2A-B55α subunit. The...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support the development and evaluation of a novel chimeric antigen receptor-macrophage (CAR-M) immunotherapy for triple-negative breast cancer (TNBC). The $218,089 award, running from April 1, 2025 to March 31, 2027, will enable researchers at the University of California, Santa Barbara to optimize an anti-CSPG4 CAR-M therapy enhanced with Rac2 activation (RACE-CAR-M) to improve tumor...
This federal Project Grant award of $545,983 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to identify molecular regulators of interactions between circulating tumor cells (CTCs) and the host immune system, with a focus on triple-negative breast cancer (TNBC). The overarching goal is to understand how CTC clusters form and interact with immune cells, in order to develop new therapeutic approaches to block CTC-mediated...
This $154,142 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by Baylor College of Medicine to examine the relationship between the molecular profiles of triple-negative breast cancer (TNBC) subtypes and the origin and function of intratumoral macrophages. The central hypothesis is that luminal TNBC subtypes are enriched for tumor-antagonistic tissue-resident macrophages (TRMs), while TNBC subtypes with mesenchymal...
This $107,948 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research conducted by the University of Pittsburgh to investigate the role of the MALT1 protein in promoting immunosuppression in triple-negative breast cancer (TNBC). The primary objectives are to: 1) Analyze how MALT1 protease activity within TNBC cells regulates the tumor immune microenvironment through the secretion of immunosuppressive cytokines, and 2) Evaluate a...